Fosfomycin: Targeted Single-Dose Treatment for Uncomplicated UTIs
| Product dosage: 3g | |||
|---|---|---|---|
| Package (num) | Per sachet | Price | Buy |
| 1 | $42.17 | $42.17 (0%) | 🛒 Add to cart |
| 2 | $37.65 | $84.34 $75.30 (11%) | 🛒 Add to cart |
| 3 | $35.81 | $126.51 $107.43 (15%) | 🛒 Add to cart |
| 4 | $35.14 | $168.68 $140.56 (17%) | 🛒 Add to cart |
| 5 | $34.74 | $210.85 $173.70 (18%) | 🛒 Add to cart |
| 6 | $34.30 | $253.02 $205.83 (19%) | 🛒 Add to cart |
| 7 | $34.14 | $295.19 $238.96 (19%) | 🛒 Add to cart |
| 8 | $34.01 | $337.36 $272.09 (19%) | 🛒 Add to cart |
| 9 | $33.80 | $379.52 $304.22 (20%) | 🛒 Add to cart |
| 10 | $33.74
Best per sachet | $421.69 $337.36 (20%) | 🛒 Add to cart |
Synonyms | |||
Fosfomycin tromethamine is a broad-spectrum bactericidal antibiotic indicated primarily for the treatment of uncomplicated urinary tract infections (UTIs) caused by susceptible strains of designated microorganisms. It exerts its effect by inhibiting the early stages of bacterial cell wall synthesis, offering a unique mechanism of action that minimizes cross-resistance with other antibiotic classes. Its convenient single-dose oral regimen supports high patient adherence and is a valuable tool in the context of growing antimicrobial resistance.
Features
- Active Ingredient: Fosfomycin tromethamine
- Available Formulation: Oral sachet (3g dose)
- Mechanism of Action: Inhibits bacterial cell wall synthesis by inactivating the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)
- Spectrum of Activity: Effective against a range of Gram-positive and Gram-negative uropathogens, including Escherichia coli, Enterococcus faecalis, and others
- FDA-Approved Indication: Uncomplicated urinary tract infections (acute cystitis) in women
- Administration: Single oral dose, mixed with water
Benefits
- High bactericidal concentration achieved rapidly in the urine, providing effective and prompt symptom relief
- Single-dose administration enhances patient compliance and reduces the risk of incomplete treatment courses
- Low potential for cross-resistance due to its unique mechanism of action, making it a useful alternative in an era of increasing antibiotic resistance
- Favorable safety and tolerability profile with a low incidence of serious adverse effects
- Minimal disruption to gut microbiota compared to longer-course antibiotic regimens
- Convenient outpatient treatment, eliminating the need for multiple prescriptions or complex dosing schedules
Common use
Fosfomycin tromethamine is primarily prescribed for the treatment of uncomplicated urinary tract infections (acute cystitis) in adult women. It is specifically indicated for infections caused by susceptible strains of Escherichia coli and Enterococcus faecalis. Its use is supported in cases where first-line treatments may be unsuitable due to resistance patterns, allergies, or tolerability issues. Off-label use may occur in certain complicated or recurrent UTIs under specialist guidance, or for surgical prophylaxis in urologic procedures, though these applications are not FDA-approved and require careful clinical judgment.
Dosage and direction
The standard adult dose for uncomplicated UTIs is a single 3g sachet of fosfomycin tromethamine, taken orally. The powder should be dissolved in half a glass (approximately 4 ounces or 120 mL) of cold water, stirred to dissolve completely, and ingested immediately. It is recommended to take the dose on an empty stomach, preferably at bedtime after emptying the bladder, to maximize urinary concentration and contact time with the pathogen. No repeat dosing is typically required for the approved indication. Dosage adjustment may be necessary in patients with severe renal impairment (creatinine clearance <10 mL/min), though specific guidelines should be followed as per prescribing information.
Precautions
Use with caution in patients with a history of hypersensitivity to fosfomycin or any component of the formulation. Although generally well-tolerated, caution is advised in patients with severe renal impairment due to reduced drug excretion. Safety in pregnancy has not been established in well-controlled studies; use during pregnancy only if clearly needed. Fosfomycin is excreted in human milk; caution is advised when administering to nursing women. As with all antibiotics, fosfomycin may promote the overgrowth of non-susceptible organisms, including fungi; monitor for signs of superinfection. Diarrhea has been reported; evaluate if prolonged or severe, as it may indicate pseudomembranous colitis.
Contraindications
Hypersensitivity to fosfomycin tromethamine or any component of the formulation. There are no other absolute contraindications specific to fosfomycin, though its use should be avoided in situations where the infection is caused by a pathogen known to be resistant to the drug, or in patients with severe hepatic impairment where data are limited. It is not indicated for the treatment of pyelonephritis or perinephric abscess.
Possible side effect
Most adverse reactions are mild to moderate and self-limiting. Commonly reported side effects include diarrhea (9%), nausea (4%), headache (4%), dizziness (2%), and vaginitis (2%). Less frequently, dyspepsia, abdominal pain, rhinitis, pharyngitis, back pain, and rash may occur. Serious side effects are rare but may include severe diarrhea (possibly indicating Clostridium difficile-associated colitis), allergic reactions (e.g., urticaria, angioedema), or exacerbation of asthma in susceptible individuals. Clinical trials and post-marketing experience suggest a generally favorable tolerability profile.
Drug interaction
Fosfomycin has a low potential for pharmacokinetic drug interactions due to minimal metabolism via cytochrome P450 enzymes and renal excretion as unchanged drug. However, metoclopramide may lower urinary concentrations of fosfomycin by accelerating gastric emptying and reducing absorption; concomitant use is not recommended. No other clinically significant interactions have been firmly established, though caution is advised when co-administering with other nephrotoxic drugs due to theoretical additive effects. Always review the patient’s full medication list before prescribing.
Missed dose
As fosfomycin is administered as a single dose for uncomplicated UTIs, the concept of a “missed dose” does not typically apply. If a patient fails to take the dose as directed, it should be taken as soon as remembered, unless it is near the time for another scheduled intervention (though none is typically scheduled). If vomiting occurs shortly after administration, consult a healthcare provider regarding potential re-dosing, though this is not standard and should be evaluated on a case-by-case basis.
Overdose
There is limited clinical experience with fosfomycin overdose. Given its mechanism and excretion profile, the most likely manifestations would be an exacerbation of known adverse effects, such as gastrointestinal disturbances (nausea, diarrhea). Management should be supportive and symptomatic. Fosfomycin is eliminated renally; hemodialysis may remove the drug in cases of significant overdose, particularly in patients with impaired renal function, though specific data are scarce. In case of suspected overdose, contact a poison control center or healthcare provider promptly.
Storage
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the sachet in its original packaging to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Once mixed with water, the solution should be consumed immediately and not stored for later use.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of medical conditions. The content provided is based on approved prescribing information and clinical guidelines but may not cover all possible uses, directions, precautions, or interactions. The author and publisher are not responsible for any errors or omissions or for any outcomes related to the use of this information. Treatment decisions should be made in consultation with a healthcare provider familiar with the patient’s individual medical history.
Reviews
“Fosfomycin has been a game-changer in my practice for uncomplicated UTIs, especially with rising resistance to trimethoprim-sulfamethoxazole. The single-dose regimen is highly appealing to patients, and I’ve observed excellent compliance and satisfaction rates.” – Dr. Elena Rostova, Urologist
“As an infectious disease specialist, I value fosfomycin for its unique mechanism and utility as a step-down oral option in select cases. It’s not a first-line agent for all UTIs, but it fills an important niche, particularly in allergic patients or those with resistant pathogens.” – Dr. Benjamin Clarke, MD
“My patients appreciate the convenience of a one-time treatment. It reduces the ‘pill burden’ and often leads to quicker symptom resolution. I’ve found it particularly useful for young, otherwise healthy women with acute cystitis.” – Pamela Deng, NP